These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 15285818)

  • 1. Development of rationally designed, target-based agents for the treatment of advanced colorectal cancer.
    Mita AC; Mita MM; Rowinsky EK
    Clin Colorectal Cancer; 2004 Jul; 4(2):107-23. PubMed ID: 15285818
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Challenges of developing therapeutics that target signal transduction in patients with gynecologic and other malignancies.
    Rowinsky EK
    J Clin Oncol; 2003 May; 21(10 Suppl):175s-186s. PubMed ID: 12743132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epidermal growth factor receptor as a therapeutic target for the treatment of colorectal cancer.
    Amador ML; Hidalgo M
    Clin Colorectal Cancer; 2004 May; 4(1):51-62. PubMed ID: 15207021
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The SRC family of protein tyrosine kinases: a new and promising target for colorectal cancer therapy.
    Lieu C; Kopetz S
    Clin Colorectal Cancer; 2010 Apr; 9(2):89-94. PubMed ID: 20378502
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel targets for anticancer treatment development in colorectal cancer.
    Macarulla T; Ramos FJ; Capdevila J; Saura C; Tabernero J
    Clin Colorectal Cancer; 2006 Nov; 6(4):265-72. PubMed ID: 17241511
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting signal transduction pathways in colorectal cancer--more than skin deep.
    Cohen SJ; Cohen RB; Meropol NJ
    J Clin Oncol; 2005 Aug; 23(23):5374-85. PubMed ID: 15998904
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutics targeting signal transduction for patients with colorectal carcinoma.
    de Bono JS; Rowinsky EK
    Br Med Bull; 2002; 64():227-54. PubMed ID: 12421735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
    Faivre S; Djelloul S; Raymond E
    Semin Oncol; 2006 Aug; 33(4):407-20. PubMed ID: 16890796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The new paradigm in the treatment of colorectal cancer: are we hitting the right target?
    Baranda J; Williamson S
    Expert Opin Investig Drugs; 2007 Mar; 16(3):311-24. PubMed ID: 17302526
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Engineering of caveolae-specific self-micellizing anticancer lipid nanoparticles to enhance the chemotherapeutic efficacy of oxaliplatin in colorectal cancer cells.
    Sundaramoorthy P; Ramasamy T; Mishra SK; Jeong KY; Yong CS; Kim JO; Kim HM
    Acta Biomater; 2016 Sep; 42():220-231. PubMed ID: 27395829
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tyrosine kinase of insulin-like growth factor receptor as target for novel treatment and prevention strategies of colorectal cancer.
    Hopfner M; Sutter AP; Huether A; Baradari V; Scherubl H
    World J Gastroenterol; 2006 Sep; 12(35):5635-43. PubMed ID: 17007015
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Roles of ERBB family receptor tyrosine kinases, and downstream signaling pathways, in the control of cell growth and survival.
    Grant S; Qiao L; Dent P
    Front Biosci; 2002 Feb; 7():d376-89. PubMed ID: 11815285
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging treatments in oncology: focus on tyrosine kinase (erbB) receptor inhibitors.
    Hamid O
    J Am Pharm Assoc (2003); 2004; 44(1):52-8. PubMed ID: 14965154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of the PI3K pathway in colorectal cancer.
    Papadatos-Pastos D; Rabbie R; Ross P; Sarker D
    Crit Rev Oncol Hematol; 2015 Apr; 94(1):18-30. PubMed ID: 25591826
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monoclonal antibodies against vascular endothelial growth factor and epidermal growth factor receptor in advanced colorectal cancers: present and future directions.
    Starling N; Cunningham D
    Curr Opin Oncol; 2004 Jul; 16(4):385-90. PubMed ID: 15187895
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monoclonal antibodies in the treatment of advanced colorectal cancer.
    Capdevila J; Saura C; Macarulla T; Casado E; Ramos FJ; Tabernero J
    Eur J Surg Oncol; 2007 Dec; 33 Suppl 2():S24-34. PubMed ID: 17981431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New strategies in colorectal cancer: biomarkers of response to epidermal growth factor receptor monoclonal antibodies and potential therapeutic targets in phosphoinositide 3-kinase and mitogen-activated protein kinase pathways.
    Dasari A; Messersmith WA
    Clin Cancer Res; 2010 Aug; 16(15):3811-8. PubMed ID: 20554751
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The pursuit of optimal outcomes in cancer therapy in a new age of rationally designed target-based anticancer agents.
    Rowinsky EK
    Drugs; 2000; 60 Suppl 1():1-14; discussion 41-2. PubMed ID: 11129167
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New molecular targets of breast cancer therapy.
    Sauer G; Deissler H; Kurzeder C; Kreienberg R
    Strahlenther Onkol; 2002 Mar; 178(3):123-33. PubMed ID: 11962188
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging therapies for colorectal cancer.
    Hezel AF; Ryan DP
    Expert Opin Investig Drugs; 2007 Jun; 16(6):867-76. PubMed ID: 17501698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.